🇺🇸 FDA

Company profile · Sponsor

SANGAMO

SANGAMO THERAPEUTICS, INC

SGMO · NYSE biotech RICHMOND, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

SANGAMO (SGMO) is a biotech company. headquartered in RICHMOND, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker SGMO
Exchange NYSE
Company type biotech
Headquarters RICHMOND, CA, USA
SEC CIK 0001001233

Pipeline (24)

Search pipeline →

  1. TX200-TR101

    SANGAMO

    Kidney Transplant Rejection

    phase 3 small molecule active

    1 trial

  2. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  3. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  4. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  5. Plerixafor

    SANGAMO

    Sickle Cell Disease

    phase 2 mab completed

    1 trial

  6. SB-318

    SANGAMO

    MPS I

    phase 2 mab terminated

    1 trial

  7. SB-509

    SANGAMO

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    4 trials

  8. SB-509

    SANGAMO

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  9. SB-728-T

    SANGAMO

    HIV

    phase 2 gene therapy completed

    2 trials

  10. SB-728mR-T

    SANGAMO

    Human Immunodeficiency Virus (HIV)

    phase 2 gene therapy completed

    1 trial

  11. SB-913

    SANGAMO

    Mucopolysaccharidosis II

    phase 2 mab terminated

    1 trial

  12. ST-400 Investigational product

    SANGAMO

    Transfusion Dependent Beta-thalassemia

    phase 2 gene therapy completed

    1 trial

  13. ST-503

    SANGAMO

    Chronic Neuropathic Pain

    phase 2 gene therapy active

    1 trial

  14. ST-920

    SANGAMO

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  15. ST-920

    SANGAMO

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  16. ST-920

    SANGAMO

    Fabry Disease

    phase 2 mab completed

    1 trial

  17. TX200-TR101

    SANGAMO

    Kidney Transplant Rejection

    phase 2 mab active

    1 trial

  18. TX200-TR101

    SANGAMO

    Prophylaxis against renal transplant rejection

    phase 2 small molecule active

    1 trial

  19. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  20. CERE-120: AAV2-NTN

    SANGAMO

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  21. SB-728-T

    SANGAMO

    HIV Infection

    phase 1 gene therapy completed

    1 trial

  22. SB-728mR-HSPC Infusion 3 days following busulfan conditioning

    SANGAMO

    HIV

    phase 1 gene therapy active

    1 trial

  23. SB-FIX

    SANGAMO

    Hemophilia B

    phase 1 mab terminated

    1 trial

  24. ZFN modified T cells

    SANGAMO

    HIV

    phase 1 mab completed

    1 trial

Patents (8)

Search patents →

  1. US 12318427

    Methods and compositions for modulation of tau proteins

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12139517

    Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12043650

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11981739

    Chimeric antigen receptor specific for interleukin-23 receptor

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11981967

    Engineering AAV

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11920169

    Compositions for linking DNA-binding domains and cleavage domains

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is SANGAMO?

SANGAMO (SGMO) is a biotech company. headquartered in RICHMOND, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does SANGAMO sponsor?

We track 24 ClinicalTrials.gov-linked programs for SANGAMO, including TX200-TR101 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does SANGAMO company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.